101. Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal
- Author
-
Gerard J. Nuovo, J. Justin Mulvey, and Cynthia M. Magro
- Subjects
Male ,Pathology ,Time Factors ,Biopsy ,Chronic lymphocytic leukemia ,Iatrogenic Disease ,B7-H1 Antigen ,Lymphocytic Infiltrate ,Granulomatous inflammation ,030207 dermatology & venereal diseases ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Skin ,medicine.diagnostic_test ,Immunoglobulins, Intravenous ,General Medicine ,Interleukin-10 ,Leukemia ,Phenotype ,Treatment Outcome ,030220 oncology & carcinogenesis ,Ibrutinib ,Rituximab ,Drug Eruptions ,medicine.drug ,medicine.medical_specialty ,Dermatology ,Drug Administration Schedule ,Pathology and Forensic Medicine ,03 medical and health sciences ,Th2 Cells ,Biomarkers, Tumor ,Humans ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,business.industry ,Adenine ,Cutaneous nodules ,Th1 Cells ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Pyrimidines ,chemistry ,Pyrazoles ,business - Abstract
A 70-year-old white man with stage C chronic lymphocytic leukemia who was being successfully treated with ibrutinib and rituximab developed bilateral, purpuric, painful cutaneous nodules. Biopsies of these nodules did not reveal the usual Th2 milieu of chronic lymphocytic leukemia but instead exhibited a Th1-rich lymphocytic infiltrate with resultant neutrophil and granulomatous inflammation. The eruption resolved with drug cessation emphasizing the potential importance of this drug in treating conditions associated with Th2 dysregulation.
- Published
- 2016